Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

about

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

Item

http://www.wikidata.org/entity/Q35779327

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@ast

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@en

type

Item

label

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@ast

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@en

prefLabel

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@ast

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@en

P1476

Bony non-union in a patient receiving androgen deprivation therapy for prostate cancer

@en

P2093

Adeel Ikram

http://www.w3.org/2001/XMLSchema#string

Ahmad Ali

http://www.w3.org/2001/XMLSchema#string

Jagwant Singh

http://www.w3.org/2001/XMLSchema#string

P2860

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial.

Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer.

Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician.

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer.

Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy.

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial.

Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs.

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.

Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).

P31

scholarly article

case report

P356

10.1136/BCR-2015-209950

http://www.w3.org/2001/XMLSchema#string

P478

2015

http://www.w3.org/2001/XMLSchema#string

P577

2015-06-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26106177

http://www.w3.org/2001/XMLSchema#string

P932

4480135

http://www.w3.org/2001/XMLSchema#string